Leveling the Playing Field for US Drug Manufacturers Against China and India

Reliance on Foreign Drug Manufacturing

• ⚠️ The US currently lacks the capacity and chemical assets to produce all necessary drugs domestically, relying on foreign sources.
• 🌍 While working with trusted countries with equivalent regulatory standards is an option, the US cannot currently produce all drugs independently without relying on China.

Onshoring Drug Manufacturing

• 💡 Companies like Oxford Pharmaceuticals in Birmingham, Alabama, demonstrate that domestic drug manufacturing can be competitive and highly automated.
• 💰 The manufacturing cost of drugs is often a small fraction of the total cost reimbursed by programs like Medicare Part D.
• 🎯 US manufacturers like Oxford can compete effectively if they are not targeted by unfair competitive practices from countries like India.

Policy Recommendations for a Level Playing Field

• ⚖️ Implementing quotas based on market dynamics can prevent countries like India from overwhelming the market and devaluing domestic drugs.
• 🇺🇸 The VA and US government should prioritize domestic manufacturing over foreign sources, which can be achieved without significant additional cost.

Systemic Flaws in Procurement

• 📉 Domestic manufacturers like Oxford lose contracts to foreign entities due to "lowest price technically acceptable" criteria, which may not adequately consider quality or reliability.
• 🔍 The VA's definition of "technically acceptable" needs to account for the superior quality and reliability of drugs manufactured in the US with better surveillance.
• 🛡️ Resilience and national security implications should be considered in government procurement to support domestic manufacturing capabilities.

Tariff Rate Quotas for Supply Chain Strength

• 📈 A well-designed tariff rate quota system can strengthen domestic production by creating guaranteed market space for US producers.
• 🔄 This system encourages reinvestment and diversification of the US supply base, leading to reduced shortages and increased resilience over time.
• ⚠️ The current market is vulnerable due to single-source dependencies on manufacturers in China and India, leading to supply shortages.